Agios Pharmaceuticals Reports Q1 GAAP EPS of -$1.69 and Revenue of $20.75M
Agios Pharmaceuticals (AGIO) reported a Q1 GAAP EPS of -$1.69, which beat estimates by $0.11, and revenue of $20.75 million, surpassing expectations by $7.41 million. The company's cash reserves decreased slightly to $1.0 billion as of March 31, 2026, from $1.2 billion as of December 31, 2025.
Tickers: $AGIO
Topics: cash reserves earnings financial results revenue growth